Roivant Sciences Anticipates $950M Payment from Moderna in July

Roivant Sciences (NASDAQ:ROIV) expects to receive a $950 million payment from Moderna in July, as outlined during its Q4 2025 earnings call. The company also highlighted anticipated readouts for mosliciguat and IMVT-1402 later this year.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · May 20, 2026, 22:21 UTC

Roivant Sciences Anticipates $950M Payment from Moderna in July

Tickers: $ROIV

Topics: clinical trials drug development pharmaceuticals

Read the full article at Seeking Alpha

More World news

Vanguard Launches Vanguard Emerging Markets Bond Active ETF (VEMB) PR Newswire · November 12, 2026, 14:10 UTC
Nvidia CEO Jensen Huang Resigns Amid National Security Concerns; Colette Kress Appointed Interim CEO TechCrunch · November 12, 2026, 14:10 UTC
Vecima Networks Reports Q1 Revenue Growth of 37.4% with Non-GAAP EPS of $0.29 Seeking Alpha · November 12, 2026, 14:04 UTC
Elysee Development Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:05 UTC
Skyline Builders Group Holding Signs Term Sheet to Acquire Majority Stake in SuperCritical Materials Seeking Alpha · November 12, 2026, 14:05 UTC
Nvidia Shares Fall Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 14:05 UTC
AeroVironment Secures $405 Million Order for Locust X3 Laser Defense Systems Seeking Alpha · November 12, 2026, 14:06 UTC
Tidewater Renewables Reports Q3 2026 Revenue Growth and Raises Full-Year EBITDA Guidance Seeking Alpha · November 12, 2026, 14:07 UTC
Ambetter from Meridian Reintroduces Marketplace Plans in Metro Detroit for 2027 PR Newswire · November 12, 2026, 14:07 UTC
Disney and Cosm Announce Multiyear Partnership to Bring Star Wars to Immersive Domes CNBC · November 12, 2026, 14:00 UTC